| value |
{"case_id":"case_15c01ea953a28c71" {"case_id":"case_15c01ea953a28c71","confidence":0.32,"corroboration":{"agreement":{"count_score":0.5,"down_count":0,"magnitude_weighted_score":0.5,"majority_direction":"neutral","neutral_count":1,"score":0.5,"up_count":0},"base_score":0.3154,"claim_graph":{"case_signal_families":["market"],"case_source_domains":["nasdaq.com"],"claims":[{"agreement_score":0.6,"claim_id":"claim_a5303f81e9ee3e33","conflict":false,"direction":"neutral","evidence_count":1,"family_coverage":1,"quality_score":0.3963,"source_coverage":1,"source_trust":0.58,"statement":"Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation","strength":0.4046}],"coverage":{"claim_count":1,"conflicting_claims":0,"dominant_claim_id":"claim_a5303f81e9ee3e33","multi_family_claims":0,"multi_source_claims":0},"score":0.3185},"contradiction":{"flags":[],"has_unresolved_conflict":false,"resolved_claims":[],"resolved_count":0,"score":0.0,"unresolved_claims":[],"unresolved_count":0},"contradiction_flags":["single_family_evidence","thin_independent_source_coverage","thin_evidence"],"evidence_event_count":1,"high_precision_pass":false,"high_trust_source_coverage":0,"independent_source_coverage":1,"low_trust_source_coverage":0,"score":0.3745,"signal_family_coverage":1,"source_trust":{"avg_score":0.58,"domains":[{"count":1,"domain":"nasdaq.com","score":0.58,"source":"Nasdaq Stocks"}],"high_trust_domains":[],"independent_high_trust_sources":1,"low_trust_domains":[]},"source_trust_score":0.377},"decision":"monitor","entity_key":"equity:PTHS","evidence_event_count":1,"headline":"Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation","personal_relevance_score":0.1,"theme_key":"entity_development","why_now":"Signal convergence: Cantor Fitzgerald Initiates Coverage of Pelthos Therapeutics (PTHS) with Overweight Recommendation [neutral]"}... |